Skip to main content
Clinical Trials/NCT02292342
NCT02292342CompletedPhase 1

An Acute, Double-blind, Randomised, Placebo-controlled, Crossover Intervention Trial Investigating the Dose-dependent Vascular Effects of Pure (-)-Epicatechin (≤1 mg/kg BW) in Healthy Men.

University of Reading1 site in 1 country21 target enrollmentStarted: May 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
21
Locations
1
Primary Endpoint
Flow mediated dilatation

Study Overview

Brief Summary

Aim: To investigate the dose-dependent vascular effect (primarily using FMD) of 3 low-level doses of pure (-)-epicatechin ≤ 1 mg/kg BW (0.1, 0.5 & 1.0 mg/kg BW) in healthy men.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Prevention
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 40 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Body Mass Index 20-27.5 kg/m2
  • •Normal blood pressure at screening (< 150/90)
  • •Non-smoker
  • •Non-vegetarian
  • •'Normal - low' chocolate consumer (<2 potions per week)
  • •'Normal - low' coffee/ tea drinker (<3 cups per day)
  • •Regular exercise routine
  • •Signed consent form

Exclusion Criteria

  • •Haemoglobin (anaemia marker) < 125 g/l
  • •Gamma GT (liver enzymes) > 80 IU/l
  • •Cholesterol > 6.5 mmol/l
  • •Suffered a myocardial infarction or stroke in the last 12 months
  • •Suffers from any cardiovascular or metabolic disorders (e.g. diabetes or any other endocrine or liver diseases)
  • •Suffers from any blood-clotting disorder, and/or takes supporting medication
  • •Any dietary restrictions or on a weight reducing diet
  • •On any lipid-modifying or blood pressure lowering medication
  • •Consuming any specific vitamin/ herbal supplements or fish oils

Arms & Interventions

0.5 mg/ kg BW pure (-)-epicatechin

Active Comparator

0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Epicatechin 0.5 mg/kg (Dietary Supplement)

0.1 mg/ kg BW pure (-)-epicatechin

Active Comparator

0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Water (Dietary Supplement)

0.5 mg/ kg BW pure (-)-epicatechin

Active Comparator

0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Epicatechin 0.1 mg/kg (Dietary Supplement)

0.1 mg/ kg BW pure (-)-epicatechin

Active Comparator

0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Epicatechin 0.1 mg/kg (Dietary Supplement)

0.1 mg/ kg BW pure (-)-epicatechin

Active Comparator

0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Epicatechin 0.5 mg/kg (Dietary Supplement)

0.1 mg/ kg BW pure (-)-epicatechin

Active Comparator

0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Epicatechin 1.0 mg/kg (Dietary Supplement)

0.5 mg/ kg BW pure (-)-epicatechin

Active Comparator

0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Epicatechin 1.0 mg/kg (Dietary Supplement)

1.0 mg/ kg BW pure (-)-epicatechin

Active Comparator

1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Epicatechin 0.1 mg/kg (Dietary Supplement)

1.0 mg/ kg BW pure (-)-epicatechin

Active Comparator

1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Epicatechin 0.5 mg/kg (Dietary Supplement)

1.0 mg/ kg BW pure (-)-epicatechin

Active Comparator

1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Epicatechin 1.0 mg/kg (Dietary Supplement)

0.0 mg/ kg BW pure (-)-epicatechin

Placebo Comparator

Water only (3 ml/kg BW)

Intervention: Epicatechin 0.1 mg/kg (Dietary Supplement)

0.0 mg/ kg BW pure (-)-epicatechin

Placebo Comparator

Water only (3 ml/kg BW)

Intervention: Epicatechin 0.5 mg/kg (Dietary Supplement)

0.0 mg/ kg BW pure (-)-epicatechin

Placebo Comparator

Water only (3 ml/kg BW)

Intervention: Epicatechin 1.0 mg/kg (Dietary Supplement)

0.0 mg/ kg BW pure (-)-epicatechin

Placebo Comparator

Water only (3 ml/kg BW)

Intervention: Water (Dietary Supplement)

1.0 mg/ kg BW pure (-)-epicatechin

Active Comparator

1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Water (Dietary Supplement)

0.5 mg/ kg BW pure (-)-epicatechin

Active Comparator

0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Intervention: Water (Dietary Supplement)

Outcomes

Primary Outcomes

Flow mediated dilatation

Time Frame: baseline to 2h

Secondary Outcomes

  • Plasma (-)-epicatechin metabolites(baseline to 24h)
  • Laser Doppler Imaging with Iontophoresis(baseline to 2h)
  • Plasma nitrate/nitrite(baseline to 2h)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jeremy Paul Edward Spencer

Professor Jeremy P.E. Spencer

University of Reading

Study Sites (1)

Loading locations...

Similar Trials